Ariceum Therapeutics
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10 Building 79 Robert-rössle-straße., Be...Phone Number
+49 3094893360Website
www.ariceum-therapeutics.comRevenue
<$5 MillionIndustry
About Ariceum Therapeutics
Ariceum Therapeutics Org Chart
Director, Clinical Trial
Director, Quality
Is Ariceum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ariceum Therapeutics had a recent Job posting/layoffs
Check out if Ariceum Therapeutics is spiking on competitors!
Check if Ariceum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ariceum Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Ariceum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ariceum Therapeutics recently announced quarterly report
Product Launch: Get notified when Ariceum Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Ariceum Therapeutics
Recommended Actions
Find VP level buyers at Ariceum Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Ariceum Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ariceum Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ariceum Therapeutics.
Ariceum Therapeutics financials insights
Gather financial insights about Ariceum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$53.5M
Ariceum Therapeutics Tech Stack
A closer look at the technologies used by Ariceum Therapeutics
Most Recent Scoops
Ariceum Therapeutics News & Media
Nusano and Ariceum Therapeutics Announce Multi-Isotope Supply Agreement
Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programs Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programsAriceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCCAriceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeuticsU.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy
225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearance Phase I/II human trials set to commence...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ariceum Therapeutics
Founded in 2021, Ariceum Therapeutics is a biotechnology company with a focus on radiopharmaceuticals to treat cancer. The company is headquartered in Berlin, Germany.... Read More